{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:02:00Z","timestamp":1767992520808,"version":"3.49.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>BRAF\/MEK inhibitor has changed the treatment landscape in patients with advanced and metastatic melanoma with prolonged overall survival and progression-free survival. Since three treatment combinations exist with similar efficacy therapy decisions are often made based on the side effect profile. Additionally, on-target side effects or class effects have to be properly managed to ensure treatment adherence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Sequential treatment with BRAF\/MEK inhibition and immunotherapy might increase toxicity with a sepsis-like syndrome and triple therapy with concomitant BRAF\/MEK inhibition and anti-PD1\/PD-L1 antibody therapy induces severe side effects in the vast majority of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Toxicity of combination therapy with BRAF\/MEK inhibitors is generally manageable, reversible and infrequently associated with treatment discontinuation. In case of persisting off-target effects the change to another combination therapy can resolve side effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000710","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T03:04:53Z","timestamp":1609470293000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["MAPK blockade, toxicities, pathogenesis and management"],"prefix":"10.1097","volume":"33","author":[{"given":"Alvaro","family":"Moreira","sequence":"first","affiliation":[{"name":"The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai"},{"name":"The Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum M\u00fcnchen (LMU), Munich, Germany"},{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Germany and Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/bjc.2013.143","article-title":"Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice","volume":"108","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy \u2013 mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"(Suppl)","key":"R8-20250526","article-title":"The anti\u2013PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600\u2013mutant melanoma: efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial","volume":"38","author":"Georgina","year":"2020","journal-title":"J Clin Oncol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","article-title":"A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors","volume":"34","author":"Rosen","year":"2016","journal-title":"Invest New Drugs"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/bjc.2017.10","article-title":"A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor","volume":"116","author":"Bendell","year":"2017","journal-title":"Br J Cancer"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"ra30","DOI":"10.1126\/scisignal.2004815","article-title":"BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling","volume":"7","author":"Sanchez-Laorden","year":"2014","journal-title":"Sci Signal"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"R28-20250526","first-page":"2801","article-title":"Systematic review of BRAF\/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)","volume":"12","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R29-20250526","article-title":"Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: a case report","volume":"7","author":"Iafolla","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ajd.12226","article-title":"Dabrafenib-associated necrobiotic granulomatous reaction","volume":"55","author":"Carlos","year":"2014","journal-title":"Australas J Dermatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1684\/ejd.2016.2747","article-title":"Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma","volume":"26","author":"Dika","year":"2016","journal-title":"Eur J Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"C339","DOI":"10.1152\/ajpcell.00144.2002","article-title":"Barrett KE. p38 mitogen-activated protein kinase inhibits calcium-dependent chloride secretion in T84 colonic epithelial cells","volume":"284","author":"Keely","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/IAE.0000000000002027","article-title":"Frequent subclinical macular changes in combined braf\/mek inhibition with high-dose hydroxychloroquine as treatment for advanced metastatic braf mutant melanoma: preliminary results from a Phase I\/II Clinical Treatment Trial","volume":"39","author":"Nti","year":"2019","journal-title":"Retina"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cpt.552","article-title":"Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches","volume":"101","author":"Brown","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.815","article-title":"Kinase inhibitors: the reality behind the success","volume":"102","author":"Jeon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","article-title":"Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","volume":"28","author":"Dr\u00e9no","year":"2017","journal-title":"Ann Oncol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","article-title":"Development of encorafenib for BRAF-mutated advanced melanoma","volume":"30","author":"Koelblinger","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J Immunother"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdx187","article-title":"Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma","volume":"28","author":"Urosevic-Maiwald","year":"2017","journal-title":"Ann Oncol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CMR.0000000000000493","article-title":"Toxicities with targeted therapies after immunotherapy in metastatic melanoma","volume":"28","author":"Grogan","year":"2018","journal-title":"Melanoma Res"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy","volume":"125","author":"Saab","year":"2019","journal-title":"Cancer"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-016-0369-8","article-title":"Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients","volume":"10","author":"Daud","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with Dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/1078-0432.CCR-18-4180","article-title":"Extended 5-year follow-up results of a Phase Ib Study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma","volume":"26","author":"Ribas","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:03:55Z","timestamp":1748300635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000710","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]}}}